In Sweden we are spoiled having a fair volume every day. It seems that you have some increasing dito over there as well. :-)
I have had a basic assumtion like this for Ceplene only (When the burnrate was at the double level.): EU is break even and the US sales is right down on the last line, every cent.
1000 whole treatments is 43 million USD, that is 1400 patients in real life because of patients falling off during the treatment. The last figure might get improved (lessend) when the treatment is optimized, though.
From the article in Wall Streat Journal:
"The FDA will get back to EpiCept a couple of months after the study application is filed in April.."
"...can hopefully start the trial late this year, looking for a launch around 2014..."
Notice the word "launch". Just to remind you all of the process that is ongoing these days concerning the SPA-protocol that will give the specific circumstances under which the phase III study will be inhibitated and Ceplene will get approval in the US.